Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	SEK 3.430	-3.92%	81,316
26-10-01	SEK 3.570	+5.00%	577,486
26-09-30	SEK 3.400	+3.03%	447,904
26-09-29	SEK 3.300	+5.77%	574,593
26-09-28	SEK 3.120	+2.30%	141,219

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 04:40:30 2026-10-02 am EDT			5-day change	1st Jan Change
3.430 ^SEK	-3.92%		+12.46%	+133.33%

Aug. 26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Market Cap	377M 37.49M 33.3M 31.14M 28.37M 53.42M 3.61B 54.15M 146M 1.84B 141M 138M 5.9B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	377M 37.49M 33.3M 31.14M 28.37M 53.42M 3.61B 54.15M 146M 1.84B 141M 138M 5.9B	EV / Sales 2026 *	4.34x	EV / Sales 2027 *	3.89x
Free-Float	72.16%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SPRINT	Delayed
Deutsche Boerse AG	5JA1	Delayed
Börse Stuttgart	5JA1	Delayed
Boerse Muenchen	5JA1	Real-time

Aug. 26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI
Jun. 26	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
Jun. 18	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
Jun. 16	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
Jun. 09	Calendar: Tuesday, June 9	FW
Jun. 08	Calendar Tuesday June 9	FW
May. 13	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
May. 13	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 16	Sprint Bioscience completes strategic evaluation of STK25 program	RE
Apr. 16	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
Apr. 14	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
Apr. 10	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

Sprint Bioscience AB Stock

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation: Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news: Sprint Bioscience AB

Analysts' recommendations: Sprint Bioscience AB

Press Releases: Sprint Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors: Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

Oct. 01	Sprint Bioscience Receives Funding from Vinnova	AQ
Sep. 02	Sprint Bioscience (Q2 review): Continued positive progress	AQ
Aug. 13	Sprint Bioscience's Upcoming Conferences and Investor Events	AQ
Jul. 23	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development	AQ
Jun. 04	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company	AQ

1 day	-2.24%
1 week	+14.43%
Current month	+2.65%
1 month	+6.40%
3 months	-14.04%
6 months	+39.60%
Current year	+137.41%

1 week	2.96	3.57
1 month	2.55	3.57
Current year	1.36	4.59
1 year	0.56	4.59
3 years	0.36	4.59
5 years	0.36	5.4
10 years	0.36	40.7

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	2023-09-30
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	2008-12-31
Jenni Björnulfson DFI	Director of Finance/CFO	55	2026-05-03

Director	Title	Age	Since
Nils Rune Nordlander CHM	Chairman	70	2009-12-31
Fredrik Lehmann BRD	Director/Board Member	50	2018-12-31
Björn Magnus Sjöstrand CHM	Chairman	58	2020-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	-2.24%	+14.43%	+505.90%	+71.08%	37.49M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-0.69%	-1.18%	+24.88%	+78.84%	59.26B
LONZA GROUP AG	+1.46%	-0.11%	+4.83%	+35.22%	47.14B
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	42.91B
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	44.13B
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	40.79B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+22.72%	29.31B
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	23.71B
Average	-0.62%	+2.37%	+98.24%	+145.91%	39.25B
Weighted average by Cap.	+0.13%	-0.32%	+58.19%	+145.93%

	2026 *	2027 *
Net sales	86.8M 8.64M 7.67M 7.17M 6.54M 12.31M 832M 12.48M 33.6M 424M 32.43M 31.73M 1.36B	96.8M 9.63M 8.56M 8M 7.29M 13.73M 927M 13.92M 37.47M 472M 36.17M 35.38M 1.52B
Net income	-	-
Net Debt	-	-